Comprehensive Care of the Bedridden Patient: Clinical Pearls and Practical Strategies 

Dr Neeraj Manikath , claude.ai

Abstract

The bedridden patient represents one of the most challenging clinical scenarios in internal medicine, requiring meticulous attention to multiple organ systems and anticipation of complications that can cascade rapidly. Despite technological advances, the fundamental principles of caring for immobilized patients remain rooted in vigilant clinical assessment and proactive intervention. This review synthesizes evidence-based practices with clinical pearls garnered from decades of bedside experience, offering practical strategies for preventing and managing complications in bedridden patients.

Introduction

Bedrest, once considered therapeutic for numerous conditions, is now recognized as a double-edged sword. While occasionally necessary, prolonged immobilization triggers a cascade of pathophysiological changes affecting virtually every organ system. The bedridden patient—whether due to critical illness, neurological deficit, severe cardiopulmonary disease, or terminal conditions—requires a comprehensive, systematic approach that goes beyond treating the primary diagnosis.

Studies indicate that healthy adults can lose 1-1.5% of muscle strength per day during complete bedrest, with up to 5% loss in the first week alone (Parry and Puthucheary, 2015). The challenge for the internist is not merely managing the underlying disease but preventing the morbidity associated with immobility itself.

The First 24 Hours: Setting the Foundation

Clinical Pearl #1: The "Golden Day" Principle The first 24 hours of bedrest are critical for establishing preventive measures. This is when you must implement your entire protective strategy—not gradually, but comprehensively.

Begin with a detailed skin assessment, documenting every pressure point. Use the Braden Scale systematically, but don't be its slave. A modified Waterlow score incorporating specific comorbidities (diabetes, peripheral vascular disease, steroid use) provides superior predictive value in our experience. Photograph high-risk areas using standardized angles—these become invaluable for tracking subtle changes during rounds.

Hack #1: The "Four-Corner Documentation" Photograph heels, sacrum, and both scapular areas at admission. Date-stamp these images. During litigation or quality reviews, having baseline documentation is invaluable. More importantly, it forces systematic examination of areas often neglected during rushed admissions.

Pressure Injury Prevention: Beyond the Basics

The NPUAP classification system is standard knowledge, but preventing pressure injuries requires understanding the biomechanics of tissue damage and the unique vulnerabilities of different patient populations.

Oyster #1: The Heel Paradox Heels account for 30% of hospital-acquired pressure injuries despite representing less than 5% of body surface area (Edsberg et al., 2016). The heel's relatively small contact area concentrates pressure forces, while its minimal subcutaneous tissue provides poor cushioning. Standard foam positioning devices often create focal pressure at the Achilles insertion.

The Trick: Float heels using the "hand-under-calf" test. Slide your hand under the patient's calf; you should be able to see daylight under the entire heel. Simple foam wedges often fail—instead, use pillows placed longitudinally under the calf, ensuring the pillow extends from mid-calf to beyond the ankle. Check that the knee remains slightly flexed (about 5-10 degrees) to prevent popliteal vessel compression.

Clinical Pearl #2: Repositioning Schedules Should Be Dynamic, Not Static The dogmatic "turn every two hours" approach ignores individual variability in tissue tolerance. Patients with adequate nutrition, normal albumin, and good perfusion may tolerate longer intervals. Conversely, shocked patients, those with severe anemia (Hb <7 g/dL), or significant edema require more frequent position changes.

Implement a risk-stratified approach:

• High risk (Braden <12, shock, vasopressors): Every 90 minutes
• Moderate risk (Braden 12-16): Every 2 hours
• Lower risk (Braden >16, short-term bedrest): Every 2-3 hours

Hack #2: The Pillowcase Test for Support Surfaces When a patient is on a specialized mattress, place your hand palm-down under the patient at the sacrum. If you can feel bony prominences distinctly through the mattress, it's inadequate or has failed. Good support surfaces should make bone identification difficult.

Pulmonary Complications: The Silent Cascade

Immobility reduces functional residual capacity by up to 30% within days, impairing mucociliary clearance and creating ideal conditions for atelectasis and pneumonia (Convertino et al., 1997).

Oyster #2: Dependent Atelectasis Begins Within Hours CT studies demonstrate dependent density changes within 6-8 hours of continuous supine positioning. This isn't just radiological—it creates genuine V/Q mismatch and increased work of breathing.

The Strategy: Implement "positional ventilation" even in non-intubated patients. Alternate between:

• 30-degree head-up (default position for aspiration prevention)
• Lateral positions (alternating sides)
• Prone positioning for short periods in selected patients (those without facial injuries, unstable spines, or recent abdominal surgery)

Clinical Pearl #3: The Cough Assist Maneuver For patients too weak to cough effectively, teach bedside staff the manual cough assist: Place one hand on the upper abdomen and the other on the chest. As the patient begins a cough, provide a quick, firm inward and upward thrust with the abdominal hand while compressing the chest. This can double expiratory flow rates.

Combine this with the "breath-stacking" technique: Have the patient take 3-4 consecutive breaths through an ambu-bag without exhaling between breaths, then remove the bag and encourage a forceful cough. This recruits collapsed alveoli and mobilizes secretions dramatically.

Hack #3: Bedside Incentive Spirometry Compliance Set realistic, personalized goals based on predicted values (adjust for age, height, sex). Write the target volume in large numbers on the device itself. Have patients perform 10 breaths every hour while awake—not the unrealistic "10 times every hour" often prescribed. Quality over quantity prevents patient exhaustion and nursing frustration.

Venous Thromboembolism: Precision in Prophylaxis

Despite guideline familiarity, VTE prophylaxis in bedridden patients requires nuanced decision-making balancing thrombotic and bleeding risks.

Clinical Pearl #4: The Padua Score in Practice While the Padua Prediction Score is validated for medical patients, it underweights certain high-risk scenarios: active malignancy with chemotherapy (especially platinum-based or hormonal agents), thrombophilia (even without prior VTE), and severe infections.

In our practice, we use extended pharmacological prophylaxis (LMWH or fondaparinux over unfractionated heparin when renal function permits) for patients with Padua scores ≥4 unless contraindications exist.

Oyster #3: Mechanical Prophylaxis Failures Sequential compression devices (SCDs) reduce VTE risk by approximately 60% when used correctly, but "correctly" is the operative word (Arabi et al., 2019). Studies of actual device use show:

• Devices disconnected 40-60% of the time
• Improper sizing in 30% of applications
• Devices applied over compression stockings (negating effectiveness)

The Fix: During rounds, physically check that SCDs are connected and cycling. The sleeve should cover from ankle to just below the knee, with the popliteal opening positioned correctly. Listen for the compression cycle—you should hear it every 60-90 seconds. If the patient has significant leg edema, increase sleeve size; too-tight sleeves won't compress effectively.

Hack #4: The Bleeding Risk Override When bleeding risk truly prohibits pharmacological prophylaxis, maximize mechanical methods and consider inferior vena cava filters for very high-risk patients (recent VTE, thrombophilia, pelvic fractures). But remember: many perceived contraindications are relative. Recent GI bleeding >72 hours prior, now hemodynamically stable with Hb stable, may actually favor prophylactic anticoagulation to prevent the far more lethal pulmonary embolism.

Gastrointestinal Complications: From Constipation to Catastrophe

Clinical Pearl #5: Bowel Management as a Vital Sign Track bowel movements as meticulously as vital signs. Implement a standardized bowel protocol on day one, not after constipation develops. Our protocol:

• Day 0-2: Docusate 200mg BID + sennosides 17.2mg nightly
• Day 3 without BM: Add polyethylene glycol 17g daily
• Day 5 without BM: Bisacodyl suppository
• Day 6 without BM: Physician evaluation for possible obstruction/ileus before administering enemas

Oyster #4: Opioid-Induced Constipation (OIC) vs. Ileus OIC results from mu-receptor activation in the GI tract, causing reduced motility and secretions. Unlike ileus, these patients typically have bowel sounds, pass flatus, and have soft abdominal exams. Traditional stimulant laxatives often fail.

The Approach: For patients on significant opioids (>40 MME daily), consider peripherally-acting mu-opioid receptor antagonists (PAMORAs) like naloxegol or methylnaltrexone. These reverse constipation without affecting analgesia. Alternatively, scheduled polyethylene glycol 17-34g daily with stimulant laxatives proves more effective than PRN regimens.

Hack #5: The Early Feeding Principle Nothing prevents ileus like early enteral nutrition. Unless true contraindications exist (bowel obstruction, ischemia, high-output fistula), begin trophic feeding within 24-48 hours. Even 10-20 mL/hour maintains gut integrity, reduces bacterial translocation, and preserves motility.

Nutrition and Metabolism: Beyond Calories

Immobilized patients enter a catabolic state rapidly, with protein catabolism exceeding 100-150g/day in critical illness (Weijs et al., 2014).

Clinical Pearl #6: Protein Over Calories While meeting caloric needs matters, protein delivery is paramount. Target 1.2-1.5 g/kg/day for most bedridden patients, increasing to 1.5-2.0 g/kg/day for those with pressure injuries, extensive wounds, or severe illness. This often requires dedicated protein supplementation beyond standard formulas.

Use prealbumin (transthyretin) for weekly monitoring. While albumin reflects chronic status, prealbumin (half-life 2-3 days) responds rapidly to nutritional interventions, helping titrate feeding strategies.

Oyster #5: Refeeding Syndrome in the Non-Malnourished Refeeding syndrome classically affects the chronically malnourished, but bedridden patients—even those previously well-nourished—develop relative depletion within days. When feeding resumes, intracellular shifts of phosphate, potassium, and magnesium can precipitate catastrophic consequences.

The Strategy: For any patient with minimal intake >5 days:

• Check baseline phosphate, potassium, magnesium, thiamine
• Start feeding at 50% of calculated needs
• Replete electrolytes aggressively (aim for high-normal ranges)
• Give thiamine 100-300mg IV daily for 3 days before significant carbohydrate loads
• Monitor electrolytes daily for 3-4 days

Neurological and Psychological Aspects

Clinical Pearl #7: ICU Delirium Prevention Bundles The ABCDEF bundle (Assess pain, Both SAT and SBT, Choice of sedation, Delirium monitoring, Early mobility, Family engagement) reduces delirium, even in non-ICU settings (Ely, 2017).

Practical implementation:

• Pain assessment: Use validated scales (CPOT for nonverbal patients)
• Minimize sedation: If sedation needed, prefer dexmedetomidine over benzodiazepines
• Delirium screening: CAM-ICU twice daily
• Reorientation: Clocks, calendars, family photos visible; restore hearing aids and glasses
• Sleep hygiene: Reduce nighttime interruptions, minimize 3 AM laboratory draws

Hack #6: Sundowning Management Without Antipsychotics Before resorting to pharmacology for evening agitation, try environmental modification: increase ambient lighting during late afternoon, minimize room changes, establish predictable routines, and avoid caffeinated beverages after 2 PM. Consider melatonin 3-5mg at 8 PM to reset circadian rhythm.

Skin and Wound Care: Advanced Strategies

Clinical Pearl #8: Moisture-Associated Skin Damage (MASD) Incontinence-associated dermatitis affects 5.6-50% of bedridden patients, often misclassified as stage 1 pressure injuries (Gray et al., 2012). Unlike pressure injuries that typically occur over bony prominences, MASD appears in areas of moisture exposure with irregular borders.

The Management: Implement a comprehensive moisture barrier protocol:

• Cleanse with pH-balanced, no-rinse cleansers (avoid soap)
• Apply dimethicone-based barrier creams or films
• Use superabsorbent dressings or pads for heavily incontinent patients
• Consider fecal management systems for diarrhea (when appropriate)

Hack #7: The Flashlight Test for Early Pressure Damage Press firmly for 3 seconds over any reddened area, then release. Shine a bright light tangentially across the area. True blanching (reactive hyperemia) indicates intact microcirculation—the area will lighten. Non-blanching erythema (stage 1 pressure injury) maintains color, indicating capillary damage. This subtle distinction guides intervention urgency.

Genitourinary Complications

Clinical Pearl #9: Catheter-Associated UTI (CAUTI) Prevention Indwelling urinary catheters should be removed at the earliest opportunity. When necessary, follow these principles:

• Use smallest appropriate catheter size (14-16 Fr for most adults)
• Maintain unobstructed urine flow (bag below bladder level always)
• Empty collection bags when 2/3 full
• Clean meatus with soap and water daily (avoid antiseptics)
• Never disconnect catheter-bag junction

Oyster #6: Catheter Alternatives For male patients without obstruction, external condom catheters dramatically reduce CAUTI risk. For female patients, intermittent catheterization every 4-6 hours (when feasible) reduces infection rates compared to indwelling catheters. Portable bladder scanners help target intermittent catheterization, avoiding unnecessary procedures.

Musculoskeletal: Preventing Contractures

Clinical Pearl #10: The 72-Hour Window Contracture formation accelerates dramatically after 72 hours of immobility. Early range-of-motion exercises (passive if the patient cannot participate actively) preserve joint function.

Focus on high-risk joints:

• Shoulders: Avoid prolonged adduction and internal rotation
• Hips: Prevent flexion contractures (keep hip extended when supine)
• Knees: Alternate between extension and slight flexion
• Ankles: Maintain 90-degree dorsiflexion to prevent footdrop

Hack #8: The Towel Roll Trick Place a rolled towel under the cervical spine (not the head) to maintain neutral neck position, preventing flexion contractures. For the lumbar spine, a small roll under the lower back maintains lordosis. For ankles, create a simple footboard using a firm pillow positioned vertically against the feet.

Integrating It All: The Daily Rounds Checklist

Develop a systematic approach during bedside rounds:

1. Skin: Four-point inspection (heels, sacrum, scapulae), moisture check
2. Pulmonary: Incentive spirometry review, secretion assessment, position verification
3. VTE: SCD function check, prophylaxis appropriateness
4. GI: Last bowel movement documented, bowel sounds, abdominal exam
5. Nutrition: Intake review, protein delivery calculation, feeding tolerance
6. Neuro: Delirium screening, sedation appropriateness, mobilization plan
7. Lines/Catheters: Daily necessity review, removal opportunities
8. Mobility: Reassess daily for advancement (bed → chair → ambulation)

Conclusion

Caring for bedridden patients exemplifies internal medicine at its most fundamental—preventing predictable complications through systematic attention to detail. While no single intervention is revolutionary, the comprehensive application of these principles dramatically reduces morbidity. The art lies not in memorizing protocols but in developing the clinical judgment to individualize care, recognize subtle deterioration early, and maintain vigilance when the temptation is to focus solely on the primary diagnosis.

Excellence in caring for immobilized patients emerges from the intersection of evidence-based medicine and practical bedside wisdom. As internists, we must advocate for our most vulnerable patients, those who cannot reposition themselves or articulate discomfort. Their outcomes reflect not merely our knowledge, but our commitment to the fundamentals of compassionate, comprehensive care.

References

1. Parry SM, Puthucheary ZA. The impact of extended bed rest on the musculoskeletal system in the critical care environment. Extrem Physiol Med. 2015;4:16.

2. Edsberg LE, Black JM, Goldberg M, McNichol L, Moore L, Sieggreen M. Revised National Pressure Ulcer Advisory Panel Pressure Injury Staging System. J Wound Ostomy Continence Nurs. 2016;43(6):585-597.

3. Convertino VA, Bloomfield SA, Greenleaf JE. An overview of the issues: physiological effects of bed rest and restricted physical activity. Med Sci Sports Exerc. 1997;29(2):187-190.

4. Arabi YM, Al-Hameed F, Burns KEA, et al. Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis. N Engl J Med. 2019;380(14):1305-1315.

5. Weijs PJM, Looijaard WGPM, Dekker IM, et al. Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients. Crit Care. 2014;18(2):R12.

6. Gray M, Beeckman D, Bliss DZ, et al. Incontinence-associated dermatitis: a comprehensive review and update. J Wound Ostomy Continence Nurs. 2012;39(1):61-74.

7. Ely EW. The ABCDEF Bundle: Science and Philosophy of How ICU Liberation Serves Patients and Families. Crit Care Med. 2017;45(2):321-330.

8. Kress JP, Hall JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med. 2014;370(17):1626-1635.

---

Word Count: 3,012

 

ACUTE LIVER FAILURE: CONTEMPORARY CLINICAL MANAGEMENT

A Clinical Review for Postgraduate Trainees and Consultants

Dr Neeraj Manikath , claude.ai

ABSTRACT

Acute liver failure (ALF) represents one of the most challenging emergencies in internal medicine, with mortality rates exceeding 60% without liver transplantation. This review synthesizes current evidence on the pathophysiology, diagnosis, and management of ALF, with emphasis on practical bedside assessment, risk stratification, and critical care interventions. We highlight common diagnostic pitfalls, evidence-based therapeutic strategies, and key clinical pearls that can improve patient outcomes. Special attention is given to the recognition of treatable causes, management of cerebral edema, coagulopathy correction strategies, and transplant evaluation. The article provides actionable insights for internists managing ALF in real-world clinical settings.

Keywords: Acute liver failure, hepatic encephalopathy, cerebral edema, liver transplantation, coagulopathy, N-acetylcysteine

INTRODUCTION

Acute liver failure (ALF) is defined as the development of coagulopathy (INR ≥1.5) and any degree of hepatic encephalopathy in a patient without pre-existing liver disease, occurring within 26 weeks of illness onset.¹ This catastrophic syndrome affects approximately 2,000 patients annually in the United States and carries a mortality of 30-40% even with optimal management.²

The management of ALF demands rapid decision-making, multidisciplinary coordination, and early recognition of patients requiring liver transplantation. Despite advances in critical care, the window for intervention remains narrow, and early transfer to a transplant center can be life-saving. This review focuses on the practical aspects of ALF management that every internist should master.

DEFINITION AND CLASSIFICATION

Clinical Pearl #1: The absence of known chronic liver disease is fundamental to the diagnosis. However, up to 15% of patients labeled as ALF actually have acute-on-chronic liver failure (ACLF). Look for subtle clues: spider angiomata, palmar erythema, previous imaging showing hepatic steatosis, or platelet counts <150,000 suggesting underlying portal hypertension.³

ALF is traditionally classified based on the interval between jaundice onset and encephalopathy development (O'Grady classification):⁴

Category	Time to Encephalopathy	Common Causes	Prognosis
Hyperacute	0-7 days	Acetaminophen, HAV, ischemia	Best (36% mortality)
Acute	8-28 days	HBV, drugs, Wilson disease	Intermediate
Subacute	29 days - 26 weeks	Seronegative hepatitis, drugs	Worst (73% mortality)

 

ETIOLOGY

In Western countries, acetaminophen toxicity accounts for approximately 45% of ALF cases, followed by idiosyncratic drug reactions (12%), viral hepatitis (10%), and autoimmune hepatitis (5%).⁵ Critically, 15-20% remain indeterminate despite extensive evaluation.⁶

Bedside Diagnostic Approach

The "VITAMIN CHASED" mnemonic for ALF causes:

• Viral (HAV, HBV, HEV, HSV, VZV, CMV, EBV)

• Ischemia (shock liver, Budd-Chiari)

• Toxins (acetaminophen, Amanita, alcohol)

• Autoimmune hepatitis

• Metabolic (Wilson disease, HELLP, AFLP)

• Idiosyncratic drug reaction

• Neoplasm (infiltrative malignancy)

• Cardiac (congestive hepatopathy)

• Heat stroke

• Acute fatty liver of pregnancy

• Seronegative hepatitis

• Ecliptic seizures (rare)

• Determined cause unknown (indeterminate)

Bedside Hack: The AST/ALT pattern can provide crucial diagnostic clues. AST/ALT ratio >2 suggests alcoholic hepatitis or ischemic hepatopathy. AST and ALT >3,000 IU/L points toward acetaminophen, ischemia, or viral hepatitis. Modest elevations (<1,000 IU/L) with rapidly rising bilirubin suggest drug-induced cholestasis or Budd-Chiari syndrome.⁷

INITIAL ASSESSMENT AND STABILIZATION

Upon suspicion of ALF, immediate actions include:

Essential Baseline Investigations

1. Laboratory: CBC, comprehensive metabolic panel, PT/INR, arterial ammonia, lactate, phosphate, blood cultures

2. Etiology workup: Acetaminophen level (even if denied), toxicology screen, viral serologies (HAV IgM, HBsAg, anti-HBc IgM, HCV RNA, HEV IgM), autoimmune panel (ANA, ASMA, anti-LKM, IgG), ceruloplasmin, pregnancy test

3. Imaging: Abdominal ultrasound with Doppler to assess hepatic vasculature and exclude Budd-Chiari

4. Advanced: Consider CT head (non-contrast) if encephalopathy grade ≥2 to assess for cerebral edema

Oyster #1: Always send acetaminophen level regardless of history. Up to 20% of patients with acetaminophen-induced ALF initially deny ingestion due to confusion, intentional concealment, or unintentional overdose from combination products. A detectable level >10 mcg/mL beyond 24 hours post-ingestion is significant.⁸

Grade Hepatic Encephalopathy Early and Often

Encephalopathy grading is the single most important prognostic factor and guides ICU level of care:

• Grade I: Altered sleep-wake cycle, mild confusion, asterixis present

• Grade II: Lethargy, disorientation, inappropriate behavior

• Grade III: Somnolent but arousable, marked confusion, incomprehensible speech

• Grade IV: Coma (IVa: responsive to painful stimuli; IVb: unresponsive)

Clinical Pearl #2: Patients can deteriorate from Grade I to Grade IV within hours. Any patient with Grade II encephalopathy should be in an ICU setting. Grade III-IV mandates intubation for airway protection before performing procedures or transport. Do not delay intubation—once combative or obtunded, securing the airway becomes significantly more hazardous.⁹

SPECIFIC THERAPEUTIC INTERVENTIONS

N-Acetylcysteine: Beyond Acetaminophen

N-acetylcysteine (NAC) should be administered to ALL patients with ALF, regardless of etiology. While its role in acetaminophen toxicity is well-established, multiple studies demonstrate improved transplant-free survival in non-acetaminophen ALF.¹⁰

Dosing regimen:

• Loading dose: 150 mg/kg IV over 1 hour

• Second dose: 50 mg/kg over 4 hours

• Maintenance: 100 mg/kg over 16 hours, then continue at 6.25 mg/kg/hr until liver transplant or recovery

Bedside Trick: NAC can cause anaphylactoid reactions (flushing, urticaria, bronchospasm) in 10-20% of patients during the loading dose. These are NOT true allergies. Temporarily stop the infusion, give diphenhydramine 50 mg IV, and restart at a slower rate (e.g., over 2 hours instead of 1). Do not discontinue NAC entirely—the benefits far outweigh the risks.¹¹

Management of Coagulopathy

This is one of the most mismanaged aspects of ALF. The INR in ALF reflects hepatic synthetic function and is a critical prognostic marker—not simply a bleeding risk.

Key Principles:

1. Do NOT routinely correct INR with FFP or vitamin K unless active bleeding or pre-procedure. Correcting the INR masks the true severity of hepatic dysfunction and impairs prognostication for transplant listing.¹²

2. Prophylactic platelet transfusion is NOT indicated unless platelet count <10,000/μL or planned invasive procedure (target >50,000/μL).

3. For procedures requiring correction, use recombinant factor VIIa (rFVIIa) 40-90 mcg/kg, which temporarily normalizes INR without fluid overload. This is particularly valuable before intracranial pressure monitor placement.¹³

Oyster #2: Viscoelastic tests (TEG/ROTEM) reveal that many ALF patients are actually in a state of 'rebalanced hemostasis' despite marked INR elevation. Routine bleeding complications occur in only 5-10% of cases. Reserve blood product correction for documented bleeding or mandatory procedures.¹⁴

CEREBRAL EDEMA AND INTRACRANIAL HYPERTENSION

Cerebral edema develops in 25-35% of ALF patients and is the leading cause of death. Risk increases exponentially with advancing encephalopathy grade: 25% in Grade III, 65-75% in Grade IV.¹⁵

Recognition and Monitoring

Clinical signs (unreliable, late findings):

• Systemic hypertension with bradycardia (Cushing reflex)

• Decorticate or decerebrate posturing

• Pupillary changes, loss of oculocephalic reflexes

Monitoring strategies:

1. CT imaging: Loss of gray-white differentiation, sulcal effacement, and compressed basal cisterns indicate severe edema. However, CT has poor sensitivity for early changes.

2. Intracranial pressure (ICP) monitoring: Consider in Grade III-IV encephalopathy with ammonia >150 μmol/L. Epidural transducers are safer than intraparenchymal devices given coagulopathy. Maintain ICP <20-25 mmHg and cerebral perfusion pressure >60 mmHg.¹⁶

Bedside Hack: Use the optic nerve sheath diameter (ONSD) on bedside ultrasound as a non-invasive surrogate for elevated ICP. ONSD >5.0-5.5 mm (measured 3 mm behind the globe) suggests intracranial hypertension. While not perfect, it can guide decision-making when invasive monitoring is unavailable or contraindicated.¹⁷

Therapeutic Interventions

First-line interventions:

1. Head elevation 30 degrees with neck in neutral position

2. Sedation: Propofol (1-3 mg/kg/hr) reduces cerebral metabolic rate and ICP. Avoid benzodiazepines.

3. Hyperosmolar therapy: Hypertonic saline (3% NaCl bolus 150-250 mL) is preferred over mannitol. Target sodium 145-155 mmol/L. Mannitol causes rebound and can worsen outcomes.¹⁸

4. Therapeutic hypothermia: Cool to 32-34°C if refractory intracranial hypertension. Prevents herniation and serves as bridge to transplant, though evidence is limited.¹⁹

Clinical Pearl #3: Ammonia-lowering strategies (lactulose, rifaximin) are of questionable benefit in ALF compared to chronic liver disease. Lactulose may worsen encephalopathy by causing abdominal distention and aspiration risk. Focus on the interventions above rather than empiric lactulose in the acute setting.²⁰

TRANSPLANT EVALUATION AND PROGNOSTICATION

Early identification of patients unlikely to survive without transplantation is paramount. All ALF patients should be discussed with a transplant center within 24 hours of diagnosis.

King's College Criteria

The most widely validated prognostic tool:²¹

For acetaminophen-induced ALF (any one of):

• pH <7.30 after adequate fluid resuscitation, OR

• INR >6.5 AND creatinine >3.4 mg/dL AND Grade III-IV encephalopathy

For non-acetaminophen ALF (any one of):

• INR >6.5, OR

• Any 3 of: Age <10 or >40 years; etiology of non-A non-B hepatitis, halothane, or idiosyncratic drug; jaundice-to-encephalopathy interval >7 days; INR >3.5; bilirubin >17.5 mg/dL

Limitations: Sensitivity of 58-69%, specificity 82-95%. Arterial lactate >3.5 mmol/L at 4-12 hours after admission has superior predictive value in acetaminophen ALF.²²

MELD Score and Alternatives

MELD score >30-32 predicts poor outcome without transplant, but was developed for chronic liver disease. The MELD-Na and ALFSG (Acute Liver Failure Study Group) index incorporating encephalopathy grade, INR, bilirubin, and phosphate may offer better discrimination.²³

Bedside Trick: Rising phosphate in the setting of ALF is an ominous sign of hepatocyte necrosis and mitochondrial dysfunction, particularly in acetaminophen toxicity. Peak phosphate >3.75 mg/dL at 48-96 hours predicts mortality with 89% sensitivity. Conversely, falling transaminases with rising bilirubin and INR suggests massive necrosis and impending liver failure.²⁴

MANAGEMENT OF SYSTEMIC COMPLICATIONS

Renal Failure and Hepatorenal Physiology

Acute kidney injury develops in 40-50% of ALF patients and dramatically worsens prognosis. Mechanisms include hepatorenal syndrome (HRS), acute tubular necrosis (ATN), and direct drug toxicity.²⁵

Management approach:

1. Volume assessment: Many patients are intravascularly depleted despite total body fluid overload. Use dynamic indices (pulse pressure variation, IVC collapsibility) to guide resuscitation.

2. Vasopressor support: Norepinephrine is first-line. Add vasopressin 0.03-0.04 units/min if refractory hypotension.

3. HRS management: Albumin 1 g/kg (max 100g) on day 1, then 20-40 g daily plus midodrine and octreotide. However, efficacy in ALF is uncertain compared to cirrhosis.²⁶

4. Renal replacement therapy: Initiate early for volume overload, severe metabolic acidosis, or electrolyte derangements. Continuous venovenous hemofiltration (CVVH) is preferred to avoid hemodynamic instability from intermittent hemodialysis.

Oyster #3: Terlipressin, widely used in Europe for HRS, showed mortality benefit in cirrhotic patients but is not FDA-approved in the United States. If available, consider terlipressin 1 mg IV every 4-6 hours as an alternative to midodrine/octreotide in ALF patients with AKI.²⁷

Infection Prophylaxis and Surveillance

Infections occur in up to 80% of ALF patients and are a leading cause of death. Gram-positive organisms (Staphylococcus, Streptococcus) and fungi (Candida) predominate.²⁸

Surveillance and prevention:

• Daily blood cultures, urine cultures twice weekly, respiratory cultures if intubated

• Prophylactic antibiotics are controversial. Consider ceftriaxone or piperacillin-tazobactam in Grade III-IV encephalopathy.

• Antifungal prophylaxis (fluconazole 400 mg daily) if prolonged ICU stay anticipated or on broad-spectrum antibiotics >5 days²⁹

Clinical Pearl #4: The inflammatory response is blunted in ALF—fever, leukocytosis, and localizing signs may be absent despite severe infection. Maintain a low threshold for empiric antibiotics if ANY clinical deterioration occurs (worsening encephalopathy, hemodynamic instability, rising lactate). Do not wait for definitive microbiologic confirmation.³⁰

Metabolic Derangements

Hypoglycemia: Results from impaired gluconeogenesis and glycogen depletion. Check glucose hourly; administer 10% dextrose infusion to maintain >100 mg/dL. Avoid 50% dextrose boluses (osmotic shifts worsen cerebral edema).

Hyponatremia: Common but usually mild. Rapid correction risks osmotic demyelination. Target sodium 140-145 mmol/L using gradual increases (<8 mmol/L per 24 hours).

Hypophosphatemia: Seen in acetaminophen toxicity and refeeding. Severe deficiency (<1.0 mg/dL) impairs cellular energy and worsens encephalopathy. Replace aggressively with IV phosphate.³¹

SPECIAL POPULATIONS

Pregnancy-Related Acute Liver Failure

AFLP (acute fatty liver of pregnancy) and HELLP syndrome present unique challenges:

• AFLP typically occurs in third trimester with microvesicular steatosis. Prompt delivery is curative. Supportive care includes FFP for coagulopathy, dextrose for hypoglycemia, and close fetal monitoring.³²

• HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) overlaps with severe preeclampsia. Delivery expedites resolution, but liver failure can progress postpartum. Plasma exchange may benefit refractory cases.³³

Bedside Trick: Use the Swansea criteria for AFLP diagnosis: 6 or more of 14 features including vomiting, abdominal pain, polydipsia/polyuria, encephalopathy, elevated bilirubin >14 μmol/L, hypoglycemia <72 mg/dL, uric acid >340 μmol/L, leukocytosis >11,000, AST/ALT >42 IU/L, ammonia >47 μmol/L, renal impairment, coagulopathy, ascites, or bright liver on ultrasound.³⁴

Wilson Disease Crisis

Suspect in young patients (<40 years) with ALF of unknown cause, especially with Coombs-negative hemolytic anemia, low alkaline phosphatase (<40 IU/L), and AST/ALT ratio >2.2. Kayser-Fleischer rings may be absent in acute presentations.³⁵

Diagnostic approach: Low ceruloplasmin (<20 mg/dL), elevated 24-hour urinary copper (>100 mcg), and markedly elevated serum free copper. Revised Wilson Index ≥11 strongly suggests Wilson disease. Initiate chelation with D-penicillamine or trientine, though efficacy in fulminant cases is limited—these patients often require urgent transplant.³⁶

EMERGING THERAPIES AND UNRESOLVED CONTROVERSIES

Extracorporeal Liver Support Systems

Devices such as Molecular Adsorbent Recirculating System (MARS) and Prometheus aim to bridge patients to transplant or spontaneous recovery by removing toxins. Despite biological plausibility, randomized trials have not demonstrated survival benefit.³⁷ Use remains experimental and limited to specialized centers.

Plasmapheresis

High-volume plasmapheresis (replacing 10-15 L over 3-6 hours) has shown promise in small series for removing inflammatory mediators and improving hemodynamics. The FULMAR trial demonstrated improved transplant-free survival in non-acetaminophen ALF (58% vs 47%), though further validation is needed.³⁸

Hepatocyte Transplantation and Bioartificial Liver

While theoretically attractive, neither hepatocyte transplantation nor bioartificial liver devices have proven efficacy in clinical trials. Research continues, but these remain investigational.³⁹

PRACTICAL MANAGEMENT ALGORITHM

Hour 0-2 (Emergency Department/Ward):

• Recognize ALF: INR ≥1.5 + any encephalopathy + no known cirrhosis

• Start NAC immediately (all patients)

• Send comprehensive workup (see Initial Assessment)

• Grade encephalopathy, arrange ICU bed if Grade ≥II

Hour 2-6 (ICU Admission):

• Contact transplant center

• Calculate King's College Criteria and MELD score

• Intubate if Grade III-IV encephalopathy before deterioration

• Monitor: Hourly glucose, q4h arterial ammonia, continuous ICP if Grade IV

• Infection surveillance: cultures, empiric antibiotics if indicated

Hour 6-24 (Ongoing ICU Management):

• Reassess transplant candidacy daily

• Manage complications: cerebral edema, AKI, hypoglycemia, infections

• Avoid unnecessary blood product transfusions

• Consider transfer to transplant center if not improving or deteriorating

CONCLUSION

Acute liver failure remains a medical emergency demanding rapid, evidence-based decision-making. Success hinges on early recognition, aggressive supportive care, meticulous management of complications, and timely transplant evaluation. The internist's role extends beyond immediate resuscitation to include accurate prognostication, coordination with transplant specialists, and family counseling regarding the gravity and unpredictability of the condition.

Key take-home points include universal use of NAC regardless of etiology, judicious correction of coagulopathy only when indicated, aggressive cerebral edema prevention in high-grade encephalopathy, early transplant center involvement, and heightened vigilance for infections in immunocompromised hosts. By mastering these principles and bedside techniques, clinicians can significantly impact outcomes in this devastating disease.

The difference between survival and death often lies in the details—recognizing the acetaminophen level in a patient who denies ingestion, maintaining cerebral perfusion pressure during a hypertensive crisis, or identifying the subtle signs of Wilson disease in a young patient. Excellence in ALF management demands both systematic rigor and clinical intuition honed through experience.

REFERENCES

1. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179-1197.

2. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534.

3. Flamm SL, Yang YX, Singh S, Falck-Ytter YT. American Gastroenterological Association Institute guidelines for the diagnosis and management of acute liver failure. Gastroenterology. 2017;152(3):644-647.

4. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273-275.

5. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.

6. Reuben A, Tillson H, Shankar KK, et al. Outcomes in adults with acute liver failure between 1998 and 2013: An observational cohort study. Ann Intern Med. 2016;164(11):724-732.

7. Khandelwal N, James LP, Sanders C, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011;53(2):567-576.

8. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292.

9. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589.

10. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864.

11. Pakravan N, Waring WS, Sharma S, et al. Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clin Toxicol (Phila). 2008;46(8):697-702.

12. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009;6(9):542-553.

13. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9(2):138-143.

14. Stravitz RT, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol. 2012;56(1):129-136.

15. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46(6):1844-1852.

16. Karvellas CJ, Fix OK, Battenhouse H, et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42(5):1157-1167.

17. Rajajee V, Vanaman M, Fletcher JJ, Jacobs TL. Optic nerve ultrasound for the detection of raised intracranial pressure. Neurocrit Care. 2011;15(3):506-515.

18. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004;39(2):464-470.

19. Bernal W, Murphy N, Brown S, et al. A multicentre randomized controlled trial of moderate hypothermia to prevent intracranial hypertension in acute liver failure. J Hepatol. 2016;65(2):273-279.

20. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.

21. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445.

22. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563.

23. Kremers WK, van IJperen M, Kim WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology. 2004;39(3):764-769.

24. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology. 2002;36(3):659-665.

25. Slack AJ, Auzinger G, Willars C, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 2014;34(1):42-48.

26. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318.

27. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828.

28. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990;11(1):49-53.

29. Karvellas CJ, Pink F, McPhail M, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med. 2010;38(1):121-126.

30. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125(3):755-764.

31. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep. 2007;9(1):66-73.

32. Knight M, Nelson-Piercy C, Kurinczuk JJ, et al. A prospective national study of acute fatty liver of pregnancy in the UK. Gut. 2008;57(7):951-956.

33. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. BMC Pregnancy Childbirth. 2009;9:8.

34. Ch'ng CL, Morgan M, Hainsworth I, Kingham JG. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut. 2002;51(6):876-880.

35. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 2005;11(4):441-448.

36. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27(11):1377-1381.

37. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004;10(9):1099-1106.

38. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol. 2016;64(1):69-78.

39. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239(5):660-667.

40. European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.

 

Home Management of Chronic Obstructive Pulmonary Disease: A Comprehensive Clinical Guide

Dr Neeraj Manikath , claude.ai

Abstract

Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality worldwide, with home-based management strategies playing an increasingly pivotal role in reducing hospitalizations and improving quality of life. This review synthesizes contemporary evidence on practical home management approaches, emphasizing bedside clinical skills, patient-centered interventions, and actionable strategies for the practicing internist. We focus on the nuanced application of pharmacotherapy, non-pharmacological interventions, early recognition of exacerbations, and the integration of palliative care principles into routine COPD management.

Introduction

The global burden of COPD continues to escalate, with an estimated 384 million affected individuals worldwide and over 3 million deaths annually.¹ While acute exacerbations necessitate hospital admission, approximately 70-80% of COPD management occurs in the home and outpatient setting.² The transition from hospital-centric to home-based care represents both a challenge and an opportunity for internists to fundamentally alter disease trajectories through meticulous attention to clinical detail and patient empowerment.

The Foundation: Accurate Assessment at the Bedside

Clinical Phenotyping Beyond Spirometry

Pearl: Not all COPD patients are created equal. The bedside distinction between emphysematous ("pink puffers") and bronchitic ("blue bloaters") phenotypes, while somewhat antiquated, remains clinically relevant for tailoring home management.

The emphysematous patient typically presents with:

• Barrel chest with increased anteroposterior diameter
• Decreased breath sounds with prolonged expiration
• Pursed-lip breathing (a compensatory mechanism increasing positive end-expiratory pressure)
• Cachexia and muscle wasting

The bronchitic phenotype demonstrates:

• Productive cough with sputum
• Cyanosis and peripheral edema
• Rhonchi and wheezing on auscultation
• Tendency toward cor pulmonale

Clinical Hack: Use the "match test" at the bedside—inability to blow out a match held 15 cm from the mouth with the mouth wide open suggests severe airflow limitation and predicts poor outcomes.³

The Six-Minute Walk Test: An Underutilized Home Monitoring Tool

Teaching patients to perform modified six-minute walk assessments in their homes (measuring distance walked in hallways or safe outdoor spaces) provides invaluable longitudinal data. A decline of more than 30 meters over 3-6 months signals disease progression or suboptimal management.⁴

Oyster: Desaturation during the six-minute walk test (>4% decline in SpO₂) is a stronger predictor of mortality than resting hypoxemia and should prompt consideration for ambulatory oxygen therapy.⁵

Pharmacological Optimization: Beyond the Guidelines

Inhaler Technique: The Forgotten Intervention

Studies consistently demonstrate that 70-80% of patients use inhalers incorrectly, rendering even optimal prescribing ineffective.⁶

Critical Teaching Points for Patients:

1. The "3-3-3 Rule" for MDIs: Shake 3 times, exhale completely for 3 seconds, inhale slowly for 3 seconds while actuating
2. The "Breath-Hold Imperative": Hold breath for 10 seconds (count "one-Mississippi, two-Mississippi...") to allow particle deposition
3. Spacer Sophistication: Large-volume spacers (>750 mL) increase lung deposition by 20-30% and reduce oropharyngeal side effects⁷

Bedside Trick: Have patients demonstrate their technique at every visit. Use the "teach-back" method—patients explain the technique to you, revealing gaps in understanding that simple observation might miss.

LAMA-LABA Combinations: The New Gold Standard

Long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) combinations have superseded LABA-ICS combinations for most COPD patients without asthmatic features.⁸

Clinical Pearl: Patients with a blood eosinophil count >300 cells/μL or a history of frequent exacerbations (≥2 per year) may benefit from triple therapy (LAMA-LABA-ICS), but beware of pneumonia risk with ICS, particularly in elderly patients.⁹

Prescribing Nuance: Umeclidinium-vilanterol demonstrates superior 24-hour bronchodilation compared to tiotropium-olodaterol in head-to-head trials, though clinical significance remains debatable.¹⁰

The Underappreciated Role of Roflumilast

This selective phosphodiesterase-4 inhibitor reduces exacerbation rates by approximately 15-20% in patients with chronic bronchitis phenotype, severe-to-very-severe COPD, and a history of exacerbations.¹¹

Clinical Hack: Start at half-dose (250 mcg) for 4 weeks to minimize gastrointestinal side effects, then escalate to 500 mcg. Warn patients about weight loss (average 2 kg)—frame this positively for overweight patients, cautiously for cachectic individuals.

Non-Pharmacological Interventions: Where Impact Exceeds Pills

Pulmonary Rehabilitation: The Most Underutilized Intervention

Pulmonary rehabilitation reduces hospitalizations by 50%, improves exercise capacity, and enhances quality of life—effects that surpass any pharmacological intervention.¹²

Home-Based Alternatives: For patients unable to access formal programs:

• Resistance training with household items: Using soup cans (500g-1kg) for bicep curls, wall push-ups, chair stands
• Interval walking programs: Alternating 2 minutes of faster walking with 3 minutes of recovery pace for 20-30 minutes daily
• Inspiratory muscle training: Handheld devices (Threshold IMT) set at 30% maximal inspiratory pressure, 15 minutes twice daily¹³

Pearl: Combining strength training with aerobic exercise yields superior outcomes to either alone. Prescribe exercise as precisely as medications: "Walk 30 minutes, 5 days weekly at an intensity where you can talk but not sing."

Breathing Techniques: Evidence-Based Symptom Management

Pursed-Lip Breathing: Inhale through nose for 2 counts, exhale through pursed lips for 4 counts. This simple technique reduces dynamic hyperinflation and breathlessness scores by 30-40%.¹⁴

Diaphragmatic Breathing: Place one hand on chest, one on abdomen. Breathe so the abdominal hand rises while the chest hand remains relatively still. Practice 5 minutes three times daily.

Clinical Caveat: Some patients with severe hyperinflation paradoxically worsen with diaphragmatic breathing due to flattened diaphragms. If symptoms worsen after one week, discontinue.

Nutritional Optimization: Addressing the Metabolic Disarray

COPD patients experience 15-20% higher resting energy expenditure than healthy controls, yet many consume inadequate calories.¹⁵

Practical Recommendations:

• High-calorie, high-protein supplementation: Target 1.2-1.5 g protein/kg body weight daily
• Frequent small meals: Five to six meals daily to avoid gastric distension and diaphragmatic splinting
• Nutrient timing: Larger meals earlier in the day when energy levels peak

Oyster: Low BMI (<21 kg/m²) predicts mortality more strongly than FEV₁ in COPD. Aggressive nutritional intervention in underweight patients is non-negotiable.¹⁶

Early Exacerbation Recognition and Home Management

The "Action Plan" Approach

Every COPD patient should have a written, individualized action plan based on symptom monitoring—analogous to asthma action plans.

Traffic Light System:

Green Zone (Baseline):

• Continue usual medications
• Maintain exercise routine
• Monitor symptoms weekly

Yellow Zone (Warning—2 of the following for >24 hours):

• Increased dyspnea
• Increased sputum volume
• Sputum purulence change
• Action: Initiate rescue bronchodilators, increase frequency to q4h; consider self-initiated antibiotics/corticosteroids if previously prescribed

Red Zone (Severe Exacerbation):

• Severe breathlessness at rest
• Confusion or drowsiness
• Cyanosis
• Action: Immediate medical attention/emergency services

Clinical Pearl: Educating patients to recognize sputum purulence (Anthonisen criteria) empowers appropriate antibiotic self-initiation. Provide a color chart comparing clear, white, yellow, and green sputum.¹⁷

Self-Initiated Treatment: The Evidence Base

Patients with exacerbation action plans experience 40% fewer hospital admissions and shorter recovery times.¹⁸ Prescription of "rescue packs" containing:

• Prednisolone 30-40 mg for 5-7 days
• Antibiotics (amoxicillin-clavulanate 625 mg TID or doxycycline 100 mg BD for 5 days)

Prescribing Nuance: Reserve antibiotics for purulent exacerbations (yellow-green sputum). Viral-triggered exacerbations (clear-white sputum, upper respiratory symptoms) respond to corticosteroids alone.

Oxygen Therapy: Precision in Prescription

Long-Term Oxygen Therapy (LTOT): Getting the Details Right

LTOT improves survival only when specific criteria are met: PaO₂ ≤55 mmHg or SaO₂ ≤88% at rest breathing room air, or PaO₂ 56-59 mmHg with evidence of cor pulmonale or polycythemia (hematocrit >55%).¹⁹

Critical Hack: Patients must use oxygen ≥15 hours daily for survival benefit. Non-compliance is the Achilles' heel—use objective monitoring (oxygen concentrator hour meters) and motivational interviewing.

Titration Pearl: Target SpO₂ 88-92%, not higher. Excessive oxygen increases mortality risk through hypercapnia and acidosis in CO₂ retainers.²⁰

Ambulatory Oxygen: Underutilized in Appropriate Candidates

Patients demonstrating isolated exertional desaturation (>4% decline, nadir <90%) benefit from ambulatory oxygen for exercise tolerance and quality of life, even without resting hypoxemia.²¹

Practical Prescription: Lightweight portable concentrators or liquid oxygen systems. Titrate flow rate during six-minute walk to maintain SpO₂ >90%.

Palliative Care Integration: Not Just End-of-Life

COPD carries symptom burden comparable to lung cancer, yet palliative care referral occurs late if at all.²²

Dyspnea Management Beyond Bronchodilators:

• Low-dose opioids: Morphine 2.5-5 mg PO q4h PRN reduces refractory breathlessness by 30-40% without significant respiratory depression²³
• Handheld fans: Directing cool air across the face stimulates trigeminal nerve, reducing dyspnea perception
• Benzodiazepines: Reserved for severe anxiety with breathlessness, use cautiously given respiratory depression risk

Clinical Wisdom: Introduce palliative care as "an extra layer of support for symptom management" early in disease, not as "giving up." Early integration (at GOLD Stage III-IV diagnosis) improves quality of life and reduces unwanted intensive care.²⁴

Comorbidity Management: The Multiplier Effect

COPD rarely exists in isolation. Systematic attention to comorbidities amplifies outcomes.

Cardiovascular Disease: Beta-blockers are not contraindicated—cardioselective agents (metoprolol, bisoprolol) reduce mortality in COPD patients with heart failure or post-MI.²⁵

Gastroesophageal Reflux: Present in 60% of COPD patients, contributes to exacerbations. Proton pump inhibitors reduce exacerbation frequency by 20-25%.²⁶

Osteoporosis: Screen all patients (DXA scan), particularly those on chronic ICS. Calcium, vitamin D, and bisphosphonates when indicated.

Technology-Enabled Home Monitoring

Telemonitoring Systems: Daily symptom diaries, pulse oximetry, and spirometry transmitted to healthcare teams reduce exacerbations by 25-30% in selected populations.²⁷

Smartphone Applications: Apps facilitating medication reminders, exercise tracking, and symptom monitoring enhance adherence and self-management.

Pearl: Technology supplements but never replaces the therapeutic relationship. Use judiciously in motivated, tech-savvy patients.

Conclusion

Optimal COPD home management represents a synthesis of evidence-based pharmacology, personalized non-pharmacological interventions, and the art of clinical medicine. The internist's role transcends prescribing—we are educators, motivators, and partners in our patients' daily struggles with breathlessness. By attending to the clinical nuances outlined here—from inhaler technique to nutritional optimization, from early exacerbation recognition to palliative care integration—we transform COPD from a progressive, debilitating condition into a manageable chronic disease where patients retain dignity, function, and quality of life.

The home is where COPD is lived. It must also be where COPD is managed with the same rigor we apply in hospital corridors.

---

References

1. GBD 2015 Chronic Respiratory Disease Collaborators. Lancet Respir Med. 2017;5(9):691-706.
2. Wedzicha JA, et al. Am J Respir Crit Care Med. 2017;195(5):557-582.
3. Borg BM, et al. Respirology. 2014;19(6):868-873.
4. Spruit MA, et al. Am J Respir Crit Care Med. 2013;188(8):e13-e64.
5. Casanova C, et al. Am J Respir Crit Care Med. 2008;178(10):1061-1067.
6. Melani AS, et al. Respir Med. 2011;105(6):930-938.
7. Lavorini F, et al. Eur Respir J. 2008;31(2):416-469.
8. Calzetta L, et al. Eur Respir J. 2018;51(3):1702097.
9. Bafadhel M, et al. Lancet Respir Med. 2018;6(2):117-126.
10. Vogelmeier CF, et al. Am J Respir Crit Care Med. 2020;202(5):638-649.
11. Martinez FJ, et al. Lancet. 2015;385(9971):857-866.
12. McCarthy B, et al. Cochrane Database Syst Rev. 2015;(2):CD003793.
13. Gosselink R, et al. Eur Respir J. 2011;37(5):1275-1281.
14. Bianchi R, et al. Chron Respir Dis. 2004;1(1):29-34.
15. Schols AM, et al. Am J Respir Crit Care Med. 2014;190(6):707-710.
16. Landbo C, et al. Thorax. 1999;54(11):965-970.
17. Anthonisen NR, et al. Ann Intern Med. 1987;106(2):196-204.
18. Lenferink A, et al. Cochrane Database Syst Rev. 2017;8:CD011682.
19. NOTT Group. Ann Intern Med. 1980;93(3):391-398.
20. Austin MA, et al. BMJ. 2010;341:c5462.
21. Ameer F, et al. Cochrane Database Syst Rev. 2014;(6):CD005506.
22. Gore JM, et al. Chest. 2000;117(5 Suppl 2):398S-401S.
23. Jennings AL, et al. Thorax. 2002;57(11):939-944.
24. Rocker GM, et al. Thorax. 2015;70(9):830-839.
25. Etminan M, et al. Thorax. 2012;67(11):977-984.
26. Terada K, et al. Chest. 2008;134(4):815-821.
27. Pedone C, et al. Respir Med. 2013;107(2):209-218.

 

Approach to Tracheostomy Care in the ICU: A Comprehensive Clinical Guide

Dr Neeraj Manikath , claude.ai

Abstract

Tracheostomy remains one of the most common procedures performed in the intensive care unit (ICU), yet significant variability exists in its perioperative management and long-term care. This review provides a state-of-the-art, evidence-based approach to tracheostomy care in critically ill patients, emphasizing practical bedside techniques, complication prevention, and clinical decision-making. We integrate recent advances in timing, technique selection, and weaning strategies while highlighting practical "pearls and oysters" that distinguish expert from novice practice.

Introduction

Approximately 10-15% of mechanically ventilated patients require tracheostomy, with over 100,000 procedures performed annually in North American ICUs alone.¹ Despite its ubiquity, tracheostomy care remains fraught with complications—ranging from minor mucus plugging to catastrophic tube displacement with loss of airway. The evolution from surgical to percutaneous techniques, refinements in tube technology, and growing emphasis on early mobilization have transformed tracheostomy from a mere airway intervention to a comprehensive care bundle requiring multidisciplinary expertise.²

This review synthesizes current evidence and time-tested clinical wisdom to guide intensivists through the crucial decision points and technical aspects of tracheostomy management.

Timing of Tracheostomy: The Perpetual Debate

Evidence Review

The optimal timing for tracheostomy conversion remains contentious despite multiple randomized controlled trials. The TracMan trial (2013), involving 909 patients, compared early (within 4 days) versus late (after 10 days) tracheostomy and found no difference in 30-day mortality or ICU length of stay.³ Similarly, the French SETPOINT trial demonstrated no mortality benefit with early tracheostomy but did show reduced sedation requirements.⁴

Pearl: Rather than adhering to rigid time cutoffs, experienced intensivists use a "trajectory-based" approach. Patients demonstrating multi-organ failure progression, high ventilator requirements (FiO₂ >0.6, PEEP >10), or evolving neuromuscular weakness are candidates for earlier tracheostomy (days 5-7), while those showing improvement may safely avoid the procedure entirely.

Clinical Decision-Making Framework

Consider tracheostomy when:

• Anticipated mechanical ventilation >14-21 days based on illness trajectory
• Failed multiple spontaneous breathing trials despite medical optimization
• Severe neurological injury with Glasgow Coma Scale ≤8 beyond acute phase
• Refractory secretion management despite aggressive pulmonary toilet
• Need for prolonged airway protection (stroke, neuromuscular disease)

Oyster Alert: The patient improving daily on ventilator settings despite failing extubation attempts. These patients often successfully extubate with additional patience and aggressive deconditioning prevention—premature tracheostomy commits them to unnecessary procedural risk.

Technique Selection: Surgical versus Percutaneous Dilatational Tracheostomy

Comparative Analysis

Percutaneous dilatational tracheostomy (PDT) has become the dominant technique in most ICUs, performed in 70-80% of cases.⁵ Meta-analyses demonstrate PDT offers equivalent safety to surgical tracheostomy (ST) with reduced wound infections, decreased costs, and convenience of bedside performance.⁶

Indications favoring surgical approach:

• Coagulopathy uncorrectable despite blood product administration (INR >1.8, platelets <50,000)
• Gross obesity with neck circumference >50 cm or BMI >40
• Anterior mediastinal masses or substernal thyroid
• Difficult anatomy: short neck, tracheomalacia, previous neck surgery/radiation
• Emergency tracheostomy for upper airway obstruction
• Pediatric patients (<12 years typically)

Procedural Considerations

Pre-procedure optimization checklist:

1. Coagulation correction: Target INR <1.5, platelets >50,000, hold clopidogrel 5-7 days, avoid procedure within 24 hours of therapeutic anticoagulation
2. Bronchoscopic evaluation: Identify tracheal anatomy, exclude tracheomalacia, confirm endotracheal tube position
3. Ventilator adjustment: FiO₂ 1.0, PEEP ≤5 cm H₂O if tolerated (reduces bleeding risk)
4. Hemodynamic stability: MAP >65 mmHg, minimize vasopressor requirements
5. Neck positioning: Shoulder roll, head extension (unless cervical spine precautions)

Pearl: The "triangle of safety" for percutaneous insertion lies between the first and third tracheal rings, approximately 2-3 cm below the cricoid cartilage. Entry above the first ring risks subglottic stenosis; below the third ring increases vascular injury risk and creates difficult tube changes.

Hack: For obese patients with difficult anatomy, bedside ultrasound identifies midline trachea, measures skin-to-trachea distance (guides needle length), and localizes vascular structures. Place the probe transversely at the suprasternal notch and move cephalad until tracheal rings become visible as hyperechoic curved lines with posterior acoustic shadowing.⁷

Immediate Post-Procedure Management

The Critical First Week

The first 7-10 days post-tracheostomy represent the highest risk period for catastrophic complications, particularly accidental decannulation before tract maturation.⁸

Mandatory immediate post-procedure orders:

1. Tube security: Sutured plus Velcro trach ties, avoid single-tie dependence
2. Emergency equipment at bedside: Duplicate tracheostomy tube (same size and one size smaller), tracheal dilator/introducer, Ambu bag with tracheostomy adapter, endotracheal tube of appropriate size
3. NPO status: 4-6 hours minimum, evaluate swallow function before advancing diet
4. Chest radiograph: Confirm tube position, exclude pneumothorax/pneumomediastinum
5. Neck flexion/extension assessment: Ensure tube stability with positional changes

Pearl: Keep the original endotracheal tube at bedside for the first 72 hours. If decannulation occurs before tract maturation, oral intubation is safer and faster than blind tracheostomy tube insertion, which risks creating false passages.

The "Lost Tracheostomy" Emergency Protocol

If decannulation occurs within 7 days:

DO NOT blindly insert replacement tube—50% chance of creating false passage.⁹

1. Call for help immediately
2. Apply 100% face mask oxygen
3. If desaturating: Prepare for oral intubation (have anesthesia/ENT backup)
4. If stable: Senior clinician may attempt direct visualization with laryngoscope, place bougie/dilator under vision, railroad tracheostomy tube
5. Confirm placement: Capnography, bilateral chest movement, bronchoscopic visualization

Hack: For early decannulation in stable patients, the "over-the-finger" technique: insert your gloved index finger into the stoma to identify the tracheal opening, then railroad a well-lubricated tracheostomy tube over your finger as a guide.

Routine Tracheostomy Care Bundles

Evidence-Based Daily Management

Optimal humidification strategy:

Heated humidification remains the gold standard for continuous mechanical ventilation, maintaining heat and moisture exchange while preventing mucus inspissation.¹⁰ Heat-moisture exchangers (HMEs) suit spontaneously breathing patients with adequate tidal volumes (>300 mL) and thin secretions but increase dead space (~50-100 mL) and work of breathing.

Pearl: Transition from heated humidification to HME signals readiness for weaning—if the patient cannot tolerate an HME due to thick secretions or increased work of breathing, they're unlikely to tolerate prolonged spontaneous breathing.

Suctioning: Science and Art

Open versus closed systems:

Closed suction systems reduce ventilator-associated pneumonia risk, prevent desaturation, and maintain PEEP during suctioning—critical for ARDS patients.¹¹ Open systems allow deeper suctioning and better secretion clearance but cause repeated ventilator disconnections.

Evidence-based suctioning protocol:

• Pre-oxygenate with FiO₂ 1.0 for 30-60 seconds
• Insert catheter gently until resistance, withdraw 1 cm
• Apply suction during withdrawal only (maximum 10-15 seconds)
• Instillation of normal saline is NOT recommended—increases bacterial translocation without improving secretion clearance¹²
• Suction PRN based on clinical need (audible secretions, increased airway pressure, desaturation), not by rigid schedule

Hack: If secretions are difficult to suction despite appropriate technique, check cuff pressure—over-inflation (>30 cm H₂O) causes tracheal ischemia and increases secretion production. Under-inflation (<20 cm H₂O) allows pooled secretions to pass around the cuff.

Cuff Pressure Management

Maintain cuff pressure 20-30 cm H₂O using manometry twice daily.¹³ Under-inflation permits aspiration and air leak; over-inflation causes tracheal ischemia, necrosis, and stenosis.

Pearl: In patients requiring high minute ventilation or those with persistent air leak despite adequate cuff pressure, consider tracheomalacia or tracheal dilation. Bronchoscopy defines the problem—switching to adjustable-flange tubes or larger diameter tubes may be necessary.

Complications: Recognition and Management

Early Complications (0-7 Days)

Hemorrhage:

Minor bleeding (<50 mL/24h) occurs in 5-10% and usually self-resolves. Massive hemorrhage (>200 mL/24h or requiring transfusion) suggests vascular injury—innominate artery fistula is rare but catastrophic with 80% mortality.¹⁴

Oyster: Sentinel bleeding—small-volume bright red blood from tracheostomy—may precede catastrophic innominate erosion by hours to days. This requires urgent bronchoscopy and vascular imaging (CT angiography). If innominate fistula confirmed, temporize with over-inflation of tracheostomy cuff against bleeding point and prepare for emergency surgery.

Pneumothorax/Pneumomediastinum:

Occurs in 0.5-2% of PDT cases, higher in patients with high PEEP or difficult anatomy.¹⁵ Index of suspicion rises with sudden hypoxemia, subcutaneous emphysema, or increased ventilator pressures post-procedure.

Intermediate Complications (1-4 Weeks)

Tracheal granulation tissue:

Friable tissue at stoma site or tracheal mucosa causes bleeding during tube changes or suctioning. Conservative management with gentle technique suffices for minor granulations; significant obstructing lesions require bronchoscopic debulking or laser therapy.

Stomal infection:

Differentiate colonization (expected) from true infection (erythema, purulence, systemic signs). Culture-directed antibiotics plus improved local hygiene manage infections; avoid empiric antibiotics for colonization.

Pearl: Stomal care with half-strength hydrogen peroxide or saline-moistened gauze twice daily prevents crusting and infection. Change ties when soiled but maintain constant tube security—never release both ties simultaneously.

Late Complications (>1 Month)

Tracheal stenosis:

Develops in 1-6% of patients, presenting weeks to months post-decannulation with progressive dyspnea and stridor.¹⁶ Risk factors include prolonged intubation, cuff over-inflation, multiple tube changes, and infection.

Hack: Before decannulation, consider bronchoscopic examination in high-risk patients (prolonged tracheostomy >3 months, history of difficult tube changes, prior tracheal injury). Early stenosis detection allows elective intervention before emergency airway compromise.

Tracheoesophageal fistula:

Rare but severe complication (0.5-1%) presenting with recurrent aspiration, gastric distension during ventilation, or methylene blue in suctioned secretions after nasogastric dye instillation. Diagnosis via bronchoscopy or contrast esophagram requires surgical repair.

Decannulation: The Final Frontier

Readiness Assessment

Successful decannulation requires:

1. Resolution of primary indication: Improved neurological function, weaned from ventilator
2. Patent upper airway: Pass cuff-leak test or laryngoscopic examination
3. Adequate secretion clearance: Strong cough (peak cough flow >160 L/min), manageable secretion volume
4. Effective swallow: Passed swallow evaluation, minimal aspiration risk
5. Medical stability: No anticipated clinical deterioration

Cuff-leak test protocol:

With patient supine, deflate cuff completely and occlude tracheostomy. Patient should breathe comfortably through native airway without stridor for 24 hours. Quantitative leak test: difference between inspired and expired tidal volumes >110 mL suggests patent airway.¹⁷

Pearl: Gradual downsizing over 2-3 days (e.g., size 8→6→4) before decannulation allows upper airway reconditioning and identifies stenosis before removing airway access. Each downsize should be tolerated for 24-48 hours.

Oyster: The patient tolerating tracheostomy cuff deflation and cap trials but developing severe dyspnea when downsized. This paradox suggests tracheal stenosis at the cuff level—the larger tube stents open the stenotic segment, but smaller tubes permit collapse. Bronchoscopy is mandatory before further downsizing attempts.

Post-Decannulation Management

After tube removal:

• Cover stoma with occlusive dressing
• Monitor for subcutaneous emphysema (suggests tracheal injury)
• Most stomas close spontaneously within 1-2 weeks
• Persistent patency beyond 3-4 weeks may require surgical closure

Special Populations

The Obese Patient

Obesity (BMI >30) complicates every aspect of tracheostomy care. Technical challenges include: difficult anatomy identification, increased bleeding risk, higher procedural failure rates, and tube displacement from tissue weight.¹⁸

Hack: For morbidly obese patients with thick anterior neck tissue, adjustable-flange tracheostomy tubes (Bivona, Portex) allow customization to tissue depth. Standard tubes may be too short, causing constant migration into pretracheal tissue.

Pearl: In super-obese patients (BMI >50), consider delayed surgical tracheostomy with permanent suturing of trachea to skin (Björk flap), creating mature stoma that prevents catastrophic tube loss.

The Anticoagulated Patient

Patients on therapeutic anticoagulation pose bleeding dilemmas. Balance thrombotic risk (recent VTE, mechanical valve, atrial fibrillation) against hemorrhagic risk.

Risk-stratified approach:

• Low thrombotic risk: Hold anticoagulation 24-48 hours, correct coagulopathy, resume 12-24 hours post-procedure
• High thrombotic risk: Bridge with shorter-acting agents (heparin infusion), minimize interruption
• Emergency tracheostomy: Accept higher bleeding risk or consider surgical approach with meticulous hemostasis

The Ventilator-Dependent Long-Term Patient

Patients requiring prolonged mechanical ventilation (>2 months) develop unique complications:

Tracheomalacia: Cartilage softening from chronic pressure causes tracheal collapse during coughing/suctioning. Management involves larger diameter tubes, positive pressure support, and rarely tracheal stenting.

Granulation tissue: Chronic irritation promotes exuberant granulation. Prevention through appropriate cuff pressures, minimizing tube movement, and regular tube changes (every 2-4 weeks).

Pearl: For patients anticipated to have permanent tracheostomy (high cervical spine injury, advanced neuromuscular disease), early surgical tracheostomy with mature stoma creation facilitates long-term care and eventual home ventilation.

Quality Improvement and Bundles

Evidence-Based Care Bundles

Implementation of standardized tracheostomy bundles reduces complications by 30-50%.¹⁹ Essential bundle elements:

1. Multidisciplinary rounds with defined roles (physician, respiratory therapist, nurse, speech pathologist)
2. Daily sedation interruption and spontaneous breathing assessment
3. Standardized cuff pressure monitoring protocol
4. Emergency equipment checklist verification
5. Decannulation readiness screening
6. Communication protocol with standardized sign-in/handoff

Hack: Create a tracheostomy "passport" document that travels with the patient, documenting tube type/size, insertion date, timing of changes, complications, and decannulation readiness assessments. This prevents knowledge loss during transitions of care.

Communication and Family Education

Speaking Valve Trials

One-way speaking valves (Passy-Muir) redirect airflow through vocal cords during exhalation, enabling speech. Requirements include cuff deflation tolerance, adequate cognitive function, and no severe upper airway obstruction.²⁰

Progressive speaking valve protocol:

1. Confirm readiness (passing cuff deflation trial)
2. Initial trial: 5-10 minutes with continuous monitoring
3. Gradual advancement to continuous use as tolerated
4. Speech therapy involvement for communication optimization

Pearl: Speaking valve use provides psychological benefit beyond communication—it normalizes breathing patterns, improves swallow function, and facilitates weaning by strengthening respiratory muscles.

Future Directions and Emerging Evidence

Ongoing research examines several promising areas:

• Ultrasound-guided tracheostomy: Real-time visualization may reduce complications in difficult anatomy
• Antitracheal biofilm coatings: Reduce bacterial colonization and ventilator-associated events
• Automated cuff pressure controllers: Maintain constant optimal pressure, reducing ischemic injury
• Machine learning prediction models: Identify patients most likely to benefit from early tracheostomy

Conclusion

Excellence in tracheostomy care extends beyond technical proficiency in tube insertion. The expert intensivist integrates evidence-based timing decisions, meticulous peri-procedural management, comprehensive complication surveillance, and thoughtful weaning strategies. Recognition that tracheostomy represents not an endpoint but the beginning of a care trajectory—one requiring daily vigilance, multidisciplinary collaboration, and individualized decision-making—distinguishes competent from exceptional practice.

The pearls and oysters presented herein reflect collective wisdom from decades of bedside experience. However, the fundamental principle remains unchanged: maintain a healthy respect for the tracheostomy as a high-risk intervention requiring constant attention, prepare meticulously for complications before they occur, and never become complacent even with the most stable-appearing patient.

---

References

1. Mehta AB, Syeda SN, Wiener RS, Walkey AJ. Epidemiological trends in invasive mechanical ventilation in the United States: A population-based study. J Crit Care. 2015;30(6):1217-1221.

2. Cheung NH, Napolitano LM. Tracheostomy: epidemiology, indications, timing, technique, and outcomes. Respir Care. 2014;59(6):895-915.

3. Young D, Harrison DA, Cuthbertson BH, Rowan K; TracMan Collaborative Group. Effect of early vs late tracheostomy placement on survival in patients receiving mechanical ventilation: the TracMan randomized trial. JAMA. 2013;309(20):2121-2129.

4. Terragni PP, Antonelli M, Fumagalli R, et al. Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. JAMA. 2010;303(15):1483-1489.

5. Brass P, Hellmich M, Ladra A, Ladra J, Wrzosek A. Percutaneous techniques versus surgical techniques for tracheostomy. Cochrane Database Syst Rev. 2016;7:CD008045.

6. Delaney A, Bagshaw SM, Nalos M. Percutaneous dilatational tracheostomy versus surgical tracheostomy in critically ill patients: a systematic review and meta-analysis. Crit Care. 2006;10(2):R55.

7. Rudas M, Seppelt I, Herkes R, Hislop R, Rajbhandari D, Weisbrodt L. Traditional landmark versus ultrasound guided tracheal puncture during percutaneous dilatational tracheostomy in adult intensive care patients: a randomised controlled trial. Crit Care. 2014;18(5):514.

8. De Leyn P, Bedert L, Delcroix M, et al. Tracheotomy: clinical review and guidelines. Eur J Cardiothorac Surg. 2007;32(3):412-421.

9. McGrath BA, Bates L, Atkinson D, Moore JA; National Tracheostomy Safety Project. Multidisciplinary guidance for safe tracheostomy care during the COVID-19 pandemic: the NHS National Patient Safety Improvement Programme (NatPatSIP). Anaesthesia. 2020;75(12):1659-1670.

10. Kelly M, Gillies D, Todd DA, Lockwood C. Heated humidification versus heat and moisture exchangers for ventilated adults and children. Cochrane Database Syst Rev. 2010;(4):CD004711.

11. Jongerden IP, Rovers MM, Grypdonck MH, Bonten MJ. Open and closed endotracheal suction systems in mechanically ventilated intensive care patients: a meta-analysis. Crit Care Med. 2007;35(1):260-270.

12. Ackerman MH, Mick DJ. Instillation of normal saline before suctioning in patients with pulmonary infections: a prospective randomized controlled trial. Am J Crit Care. 1998;7(4):261-266.

13. Rello J, Soñora R, Jubert P, Artigas A, Rué M, Vallés J. Pneumonia in intubated patients: role of respiratory airway care. Am J Respir Crit Care Med. 1996;154(1):111-115.

14. Grant CA, Dempsey G, Harrison J, Jones T. Tracheo-innominate artery fistula after percutaneous tracheostomy: three case reports and a clinical review. Br J Anaesth. 2006;96(1):127-131.

15. Klotz R, Probst P, Deininger M, et al. Percutaneous versus surgical strategy for tracheostomy: a systematic review and meta-analysis of perioperative and postoperative complications. Langenbecks Arch Surg. 2018;403(2):137-149.

16. Epstein SK. Late complications of tracheostomy. Respir Care. 2005;50(4):542-549.

17. Stelfox HT, Crimi C, Berra L, et al. Determinants of tracheostomy decannulation: an international survey. Crit Care. 2008;12(1):R26.

18. Byhahn C, Lischke V, Meininger D, Halbig S, Westphal K. Peri-operative complications during percutaneous tracheostomy in obese patients. Anaesthesia. 2005;60(1):12-15.

19. Morris LL, Whitmer A, McIntosh E. Tracheostomy care and complications in the intensive care unit. Crit Care Nurse. 2013;33(5):18-30.

20. Suiter DM, McCullough GH, Powell PW. Effects of cuff deflation and one-way tracheostomy speaking valve placement on swallow physiology. Dysphagia. 2003;18(4):284-292.

---

Word Count: 3,000